This was the stock's third consecutive day of gains.

We recently compiled a list of the 15 Stocks to Invest in with Steady Dividends. In this article, we are going to take a look ...

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

Bristol Myers Squibb plans to release initial late-stage trial data on Cobenfy in Alzheimer's-related psychosis during the ...

We came across a bullish thesis on Bristol-Myers Squibb Company (BMY) on Disruptive analytics’ Substack by Magnus Ofstad. In ...

Bristol-Myers Squibb Co (BMY) stock saw a modest uptick, ending the day at $57.04 which represents a slight increase of $0.75 or 1.33% from the prior close of $56.29. The stock opened at $56.63 and ...

Bristol Myers Squibb CEO Chris Boerner described Cobenfy, a new drug to treat schizophrenia and may also help with bipolar ...

Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and ...

Ameritas Advisory Services LLC increased its holdings in shares of Bristol-Myers Squibb (NYSE:BMY – Free Report) by 9.4% in ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

To get a sense of who is truly in control of Bristol-Myers Squibb Company ( NYSE:BMY ), it is important to understand the ...

Bristol Myers Squibb CEO Chris Boerner described his company's new drug, Cobenfy, which can be used to treat psychiatric disorders like schizophrenia. He said the treatment is effective but doesn ...